Longboard Pharmaceuticals, Inc. - LBPH STOCK NEWS

Longboard Pharmaceuticals (Nasdaq: LBPH) announced successful completion of the multiple ascending dose (MAD) phase of its Phase 1 trial for LP352, aimed at treating severe epilepsies. The company plans to initiate a Phase 1b/2a trial for approximately 50 participants with developmental and epileptic encephalopathies in Q1 2022. Ongoing IND-enabling studies for LP143 and LP659 are set for IND submissions in 2022. As of September 30, 2021, Longboard reported cash reserves of $112.6 million and a net loss of $6.3 million, up from $2.6 million in the same quarter of 2020.

Longboard Pharmaceuticals (Nasdaq: LBPH) announced the appointment of Steven W. Spector as General Counsel on November 2, 2021. Spector, who has significant experience in drug development and corporate law, has been advising Longboard since its inception. He has previously served as General Counsel for Arena Pharmaceuticals for almost two decades and held roles with other public companies. Longboard focuses on developing transformative medicines for neurological diseases and has a portfolio of drug candidates targeting specific G protein-coupled receptors.

Longboard Pharmaceuticals (Nasdaq: LBPH) announced that its senior leadership will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 11:20 AM ET. This event will allow investors and stakeholders to gain insights into the company's pipeline focused on neurological diseases. A live webcast of the presentation can be accessed via the Investors Relations section of Longboard's website, with a replay available for at least 30 days post-event.

Longboard Pharmaceuticals (Nasdaq: LBPH) announced positive results from its Phase 1 clinical trial of LP352, a next-generation 5-HT2c receptor superagonist for treating developmental and epileptic encephalopathies (DEEs). The trial assessed safety, tolerability, and pharmacokinetics in healthy volunteers, with favorable outcomes and mild adverse events. The company plans to initiate a Phase 1b/2a clinical trial in Q1 2022, aiming to evaluate the efficacy of LP352 in patients with treatment-resistant seizures. The initial findings suggest LP352's potential to reduce seizures effectively.

Longboard Pharmaceuticals (Nasdaq: LBPH) announced that President & CEO Kevin R. Lind will present at two investor conferences: Citi’s 16th Annual BioPharma Virtual Conference on September 8, 2021, at 3:15 PM ET, and H.C. Wainwright’s 23rd Annual Global Investment Conference, with webcasts starting September 13, 2021, at 7:00 AM ET. Live webcasts can be accessed via Longboard’s Investor Relations webpage. Longboard focuses on developing innovative medicines for neurological diseases, with key product candidates LP352, LP143, and LP659 aimed at treating various neurological conditions.

Longboard Pharmaceuticals (NASDAQ: LBPH) has made significant strides in its clinical trials, particularly with LP352, which is currently in the multiple ascending dose (MAD) phase of a Phase 1 trial, with topline results anticipated in 2021. The company is also advancing its IND-enabling studies for LP143 and LP659, focusing on treatments for neurodegenerative diseases. Financially, Longboard reported a net loss of $7.0 million for Q2 2021, up from $1.6 million the previous year, with R&D expenses increasing to $4.9 million, primarily due to LP352 trial costs.

Longboard Pharmaceuticals has commenced the multiple ascending dose (MAD) portion of its Phase 1 study for LP352, targeting severe epilepsy, with topline results expected by the end of 2021. The company successfully raised approximately $84.8 million through an upsized IPO and strengthened its leadership team, adding experienced members in key R&D roles. Financial results for Q1 2021 show a net loss of $5.7 million on R&D expenses of $4.4 million, while cash reserves stand at $120.9 million, positioning the company well for future clinical trials.

Longboard Pharmaceuticals has priced its initial public offering (IPO) of 5,000,000 shares at $16.00 each, aiming to raise $80 million before expenses. The shares will trade on the Nasdaq under the symbol LBPH, starting March 12, 2021. The offering will close on March 16, 2021, with an option for underwriters to purchase an additional 750,000 shares. Formed in January 2020, Longboard focuses on neurological diseases using innovative GPCR-targeted therapies. This IPO positions the company for growth and further development of its promising product candidates.

Longboard Pharmaceuticals has appointed Brandi L. Roberts as its new Chief Financial Officer (CFO). Her extensive experience in the life sciences sector is expected to drive the company’s financial strategies as it advances treatments for neurological diseases. Previously, Roberts held CFO positions at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, accumulating over 25 years in public accounting and finance. Longboard focuses on developing innovative medicines for conditions such as developmental and epileptic encephalopathies, and neurodegenerative diseases.